IP Library Granted Patent US 9,642,868
Granted Patent B2
US 9,642,868 · App. 14/545,014 · Granted May 9, 2017

Topical agents for the treatment of sensory discomfort in the nasal cavity

Inventor: Edward T. Wei (Berkeley, CA)
A61K31/66A61K9/0043A61M35/006A61M2210/0618
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,642,868
App. No.
14/545,014
Granted
May 9, 2017
Kind
B2
Abstract

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-alkyl-phosphinoyl-alkanes as described herein, DIPA-1-8 and DIPA-1-9, and 2-6 and 2-7 that are collectively referred to herein as “DAPA compounds”, that are useful in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by inflammation, irritation, itch, or pain) in the nasal cavity. The applicant has found that localized delivery of DAPA compounds with a swab to the Kiesselbach's area of the human nose will relieve the discomforts of rhinitis and other nasal cavity discomforts.

Claims (4)

1. A method of relieving sensory discomfort in a nasal cavity, comprising:

providing an aqueous liquid composition, the composition having a therapeutic amount of 1-[Diisopropyl-phosphinoyl]-nonane; and, topically applying the aqueous liquid composition to the Kiesselbach's area of a human nose in need thereof to relieve nasal discomfort caused by air pollutants, rhinitis, the common cold or rhinosinusitis.

2. The method of relieving sensory discomfort in the nasal cavity as in claim 1 , wherein the therapeutic amount of 1-[Diisopropyl-phosphinoyl]-nonane is 1 to 10 mg/mL of the composition.

3. The method of relieving sensory discomfort in the nasal cavity as in claim 2 wherein the aqueous liquid composition is saturating an absorbent material.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2022
From: IVIEW THERAPEUTICS, INC.
To: WEI, EDWARD T.
Reel/Frame 059688/0298 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2021
From: ORINDA PHARMA, INC.
To: IVIEW THERAPEUTICS, INC.
Reel/Frame 056148/0250 →
Priority Claims (2)
WO PCT/GB2013/052750 · Oct 22, 2013 · international
WO PCT/GB2013/052751 · Oct 22, 2013 · international
Continuity (3)
Continuation In Part PCTGB2013052750 · Oct 22, 2013
Continuation In Part PCTGB2013052751 · Oct 22, 2013
Related Publication 20150265752A1 · Sep 24, 2015